About NormaxAI

Our team comprises leading experts with decades of experience in medicine, engineering, technology, and artificial intelligence. This unique combination of knowledge and skills allows us to develop groundbreaking solutions for personalized cancer care.

• Leadership: Led by CEO & Chairman Peter Jensen, our team boasts extensive experience across various disciplines, ensuring a holistic approach to tackling complex challenges in cancer treatment.
• Medical Expertise: With renowned medical advisors like Dr. Michael Hogarth and Dr. Charles Bennett, we ensure that our technologies are grounded in sound medical science and clinical best practices.
• Technology & AI: Our team of engineers and AI specialists, led by CTO Mitch Goldberg and Chief Software Engineer Lee Abell,are at the forefront of developing and applying AI for personalized medicine.

NormaxAI is committed to developing and deploying innovative solutions that address the growing challenges in cancer treatment. We focus on:

• Personalized Medicine: Tailoring therapies to each patient’s unique genetic profile for optimal efficacy and minimal side effects.
• AI-powered Diagnostics & Treatment: Leveraging the power of artificial intelligence to analyze patient data, identify treatment targets, and develop personalized therapies.
• Virtual Tumor Board (VTB): Providing a collaborative platform for oncologists and specialists to remotely discuss cases,share expertise, and optimize treatment plans.
• EARTh GMP Process: Developing personalized mRNA vaccines and immunotherapies that target specific neoantigens in each patient’s tumor.

We envision a future where cancer patients have access to personalized, effective, and affordable treatments. By harnessing the power of AI and cutting-edge biotechnology, we aim to improve patient outcomes, extend lives, and ultimately, contribute to a world free from cancer.